Pharmaceutical Approval Update.
Kaufman MB.
P T · other; journal article PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för crisaborole. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
19 träffarDefibrotide.
Baker DE, Demaris K.
Hosp Pharm · research-article; journal article · DOI 10.1310/hpj5110-847Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled Study in Healthy Volunteers.
Zane LT, Hughes MH, Shakib S.
Am J Clin Dermatol · research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1007/s40257-016-0204-6Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, Eichenfield LF, Forsha DW, Rees WC, Simpson EL, Spellman MC, Stein Gold LF, Zaenglein AL, Hughes MH, Zane LT, Hebert AA.
J Am Acad Dermatol · clinical trial, phase iii; randomized controlled trial; journal article · DOI 10.1016/j.jaad.2016.05.046Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.
Dong C, Virtucio C, Zemska O, Baltazar G, Zhou Y, Baia D, Jones-Iatauro S, Sexton H, Martin S, Dee J, Mak Y, Meewan M, Rock F, Akama T, Jarnagin K.
J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.116.232819Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.
Zane LT, Chanda S, Jarnagin K, Nelson DB, Spelman L, Gold LS.
Immunotherapy · review; journal article · DOI 10.2217/imt-2016-0023Assessing the New and Emerging Treatments for Atopic Dermatitis.
Eichenfield LF, Friedlander SF, Simpson EL, Irvine AD.
Semin Cutan Med Surg · journal article · DOI 10.12788/j.sder.2016.043Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study.
Zane LT, Kircik L, Call R, Tschen E, Draelos ZD, Chanda S, Van Syoc M, Hebert AA.
Pediatr Dermatol · research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1111/pde.12872Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
Jarnagin K, Chanda S, Coronado D, Ciaravino V, Zane LT, Guttman-Yassky E, Lebwohl MG.
J Drugs Dermatol · research support, non-u.s. gov't; review; journal articlePost Hoc Analyses of the Effect of Crisaborole Topical Ointment, 2% on Atopic Dermatitis: Associated Pruritus from Phase 1 and 2 Clinical Studies.
Draelos ZD, Stein Gold LF, Murrell DF, Hughes MH, Zane LT.
J Drugs Dermatol · research support, non-u.s. gov't; journal articlePharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study.
Tom WL, Van Syoc M, Chanda S, Zane LT.
Pediatr Dermatol · clinical trial, phase ii; research support, non-u.s. gov't; journal article · DOI 10.1111/pde.12780A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
Stein Gold LF, Spelman L, Spellman MC, Hughes MH, Zane LT.
J Drugs Dermatol · clinical trial, phase ii; research support, non-u.s. gov't; randomized controlled trial; journal articleCrisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
Murrell DF, Gebauer K, Spelman L, Zane LT.
J Drugs Dermatol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal articleA review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.
Moustafa F, Feldman SR.
Dermatol Online J · review; journal article · DOI 10.5070/d3205022608An assessment of the genetic toxicology of novel boron-containing therapeutic agents.
Ciaravino V, Plattner J, Chanda S.
Environ Mol Mutagen · journal article · DOI 10.1002/em.21779Gateways to clinical trials.
Tomillero A, Moral MA.
Methods Find Exp Clin Pharmacol · bibliography; journal articleAN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis.
Nazarian R, Weinberg JM.
Curr Opin Investig Drugs · review; journal articleGateways to clinical trials.
Tomillero A, Moral MA.
Methods Find Exp Clin Pharmacol · bibliography; journal articleDiscovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
Akama T, Baker SJ, Zhang YK, Hernandez V, Zhou H, Sanders V, Freund Y, Kimura R, Maples KR, Plattner JJ.
Bioorg Med Chem Lett · comparative study; journal article · DOI 10.1016/j.bmcl.2009.03.007